BioNTech’s Cancer Pivot Gains Momentum with Faster Trial Path, But Berlin’s Vaccine Contracts Cast a Shadow
03.06.2026 - 21:02:16 | boerse-global.de
BioNTech is rewriting the playbook for its lead lung-cancer study in a bid to reach the market faster, even as the German government reminds the biotech giant of its lingering obligations to keep COVID-19 vaccine production lines warm at home. The contrast between the company’s forward-looking oncology strategy and the rearview mirror of pandemic-era contracts is becoming the central investment narrative.
A quicker route to the regulator’s door
At the ASCO congress in Chicago, BioNTech and partner Bristol Myers Squibb announced a redesign of their pivotal ROSETTA-Lung02 trial. The primary endpoint has been switched from overall survival to progression-free survival (PFS), a metric that can be read out earlier. Co-founder and chief medical officer Ă–zlem TĂĽreci made clear that a positive PFS result would open the door to early discussions with regulators such as the FDA. Overall survival remains a secondary endpoint, but it no longer sits at the statistical core of the study.
The Phase 2 data that underpinned the change are already on the table: confirmed response rates of 57.1% in patients with non-squamous non-small cell lung cancer (NSCLC) and 68.4% in the squamous subgroup. The shift is also a tactical move in a crowded bispecific field. Rivals Pfizer and the Summit Therapeutics–Akeso alliance are developing similar PD-(L)1xVEGF bispecifics; Pfizer still uses overall survival as the primary endpoint in some of its Phase 3 trials. Being first to market in oncology can mean billions in revenue.
Berlin’s stockpile and standby contracts
While BioNTech’s oncology pipeline advances, its COVID-19 legacy is creating political friction at home. The German health ministry confirmed that 7.6 million doses of the Comirnaty LP.8.1 vaccine remain stored in the central federal depot. No further deliveries are planned, as existing contracts have been fulfilled. The real tension lies elsewhere: BioNTech has announced it will shut down its German production sites for COVID-19 vaccines, shifting all future manufacturing to Pfizer’s facilities in Europe and the US.
Should investors sell immediately? Or is it worth buying BioNTech?
That plan collides with a government standby agreement designed to secure production capacity in a crisis. Germany holds such contracts with three domestic companies: BioNTech, IDT Biologika, and Wacker/Corden Pharma. The ministry said it would need to examine the consequences if BioNTech can no longer meet the contract’s requirements because of the closures. Green party budget politician Paula Piechotta has called for a review of whether the contracts could be used to compel BioNTech to maintain German manufacturing capacity. The federal budget for 2026 allocates €336 million for pandemic standby contracts, with about €175 million planned for 2027. The agreements run between 2027 and 2029.
Financial firepower meets a costly transformation
BioNTech’s balance sheet remains robust: cash and securities of around €16.8 billion, and a share buyback programme of up to $1 billion running until May 2027. But the operational pivot is expensive. The company’s 2026 revenue guidance stands at €2.0–2.3 billion, reflecting lower COVID-19 vaccine sales. First-quarter 2026 revenues came in at €118.1 million, producing a net loss of €531.9 million.
Analysts are cautiously constructive. UBS upgraded the stock to “Buy” at the end of May, lifting its price target from $117 to $135. The average target among 19 analysts is roughly $130, with a consensus of “Moderate Buy.” Jefferies rates the shares “Buy” with a target of $138. Analyst Akash Tewari pointed to early oncology programmes in NSCLC but saw no clear differentiation from competitor Ivonescimab yet, adding that longer-term advantages depend on novel combination therapies.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Stock under pressure despite pipeline promise
The share price tells a less optimistic story. At around €76, BioNTech stock trades more than 27% below its 52-week high of €105.80 and sits beneath its moving averages. Over the past twelve months, it has lost roughly a quarter of its value. The next concrete catalysts are further data from ROSETTA-Lung02 and new results from the antibody-drug conjugate programmes, both expected later this year. Whether the oncology pipeline can close the valuation gap will depend on those readouts — while the debate in Berlin over production sites continues to shadow the transformation.
Ad
BioNTech Stock: New Analysis - 3 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
